Usha Chakravarthy a, ⁎
, Roy Schwartz b, c, Robyn H. Guymer d, Frank G. Holz e, Aleksandra V. Rachitskaya f, Stela Vujosevic g, h, Philip Lewis h, Hanne Vorwerk i, #
Employee of Apellis Pharmaceuticals at the time of the study.
, A. Yasin Alibhai j, Eric M. Moult k, Marco U. Morales l, #
Employee of Apellis Pharmaceuticals at the time of the study.
, Caleb Bliss l, Caroline R. Baumall m, Nadia K. Waheed m
a From the Royal Victoria Hospital (U.C.), Queen's University of Belfast, Institute of Clinical Science, Belfast, United Kingdom
b Apellis UK Limited (R.S.), London, United Kingdom
c Moorfields Eye Hospital Foundation Trust (R.S.), London, United Kingdom
d Centre for Eye Research Australia (R.H.G.), Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, Victoria, Australia
e Department of Ophthalmology (F.G.H.), University of Bonn, Bonn, Germany
f Cleveland Clinic (A.V.R.), Cleveland, Ohio, USA
g Department of Biomedical, Surgical and Dental Services (S.V.), University of Milan, Milan, Italy
h Eye Clinic (S.V., P.L.), IRCCS MultiMedica, Milan, Italy
i Apellis Germany GmbH (H.V.), Germany Bavaria Towers, Munich, Germany
j Boston Image Reading Center (A.Y.A.), Boston, Massachusetts, USA
k Massachusetts Institute of Technology (E.M.M.), Cambridge, Massachusetts, USA
l Apellis Pharmaceuticals (M.U.M., C.B., C.R.B.), Waltham, Massachusetts, USA
m New England Eye Center (C.R.B., N.K.W.), Boston, Massachusetts, USA